NCT02833883View on ClinicalTrials.gov

Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

January 13, 2023

Study Completion Date

January 13, 2023

Conditions
Prostate CancerCastration Resistant Prostate Cancer
Interventions
DRUG

Enzalutamide

DRUG

CC-115

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

21287

John Hopkins Medical Center, Baltimore

27701

Duke University Medical Center, Durham

94143

University of California San Francisco, San Francisco

98109

University of Washington School of Medicine, Seattle

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER